SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Silva Francisco – ‘4’ for 11/21/22 re: BioRestorative Therapies, Inc.

On:  Monday, 11/21/22, at 5:14pm ET   ·   For:  11/21/22   ·   As:  Director and Officer   ·   Accession #:  1567619-22-20707   ·   File #:  1-37603

Previous ‘4’:  ‘4’ on 11/4/22 for 11/3/22   ·   Next:  ‘4’ on / for 2/17/23   ·   Latest:  ‘4’ on 3/20/24 for 3/18/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/21/22  Silva Francisco                   4          Dir.,Off.   1:14K  BioRestorative Therapies, Inc.    Broadridge Fin’l… Inc/FA

Statement of Changes in Beneficial Ownership of Securities by an Insider   —   Form 4   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 4           Statement of Changes in Beneficial Ownership of     HTML     14K 
                Securities by an Insider -- doc1.xml/3.6                         




        

This ‘4’ Document is an XML Data File that may be rendered in various formats:

  Form 4    –   Plain Text   –  SEC Website  –  EDGAR System  –    XML Data    –  <?xml?> File
 

 
SEC Info rendering:  Statement of Changes in Beneficial Ownership of Securities by an Insider
 
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Silva Francisco

(Last)(First)(Middle)
40 MARCUS DRIVE

(Street)
MELVILLENY11747

(City)(State)(Zip)
2. Issuer Name and Ticker or Trading Symbol
BioRestorative Therapies, Inc. [ BRTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector 10% Owner
XOfficer (give title below) Other (specify below)
VP of Research and Development
3. Date of Earliest Transaction (Month/Day/Year)
11/21/22
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock 11/21/22P 943A$2.6162166,046 (1)D
Common Stock 12,136IIRA
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$3,000 (2) 12/7/22Common Stock1 1D
Stock Option$3,000 (2) 10/4/23Common Stock1 1D
Stock Option$3,000 (2) 2/18/24Common Stock3 3D
Stock Option$3,000 3/12/14 3/11/24Common Stock1 1D
Stock Option$3,000 (2) 10/23/24Common Stock9 9D
Stock Option$3,000 (2) 9/4/25Common Stock6 6D
Stock Option$3,000 (2) 6/10/26Common Stock15 15D
Stock Option$3,000 (2) 7/12/27Common Stock20 20D
Stock Option$3,000 (2) 10/29/28Common Stock25 25D
Stock Option$5.08 (3) 3/18/31Common Stock293,479 293,479D
Stock Option$5.08 (4) 11/4/31Common Stock42,059 42,059D
Explanation of Responses:
(1)  Includes 101,972 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,037 shares on December 18, 2022 and February 18, 2023, 1,036 shares on January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
(2)  The option is currently exercisable.
(3)  The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
(4)  The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.
/s/ Francisco Silva 11/21/22
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
____________
Transaction Code:
    P    Open market or private purchase of non-derivative or derivative security.

Top
Filing Submission 0001567619-22-020707   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 5:36:57.1am ET